Kintz Samuel's Form 4/A amendment
AmendedEnliven Therapeutics, Inc.ELVN · filed Aug 21, 2025
- Accession no.
- 0001415889-25-022649
- Filed
- Aug 21, 2025
- Trade date
- Aug 20, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
- Original filed
- Aug 20, 2025
This filing lists 1 non-derivative transaction. It carries over 2 transactions from the original filing that it did not restate. Open-market sales total $250.2K. It was filed 1 day after the trade.
This amendment restates part of 0001415889-25-022459 (filed Aug 20, 2025). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kintz SamuelCIK 0001967168 | Director, Officer (PRESIDENT AND CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2025 | Common Stock | SSaleDisposed | −1,517 | $20.00F3 | −$30,340 | 927,892 | Indirect |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001415889-25-022459 (filed Aug 20, 2025).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | Common Stock | SSaleDisposed | −10,393 | $20.02F2 | −$208,067.86 | 929,999 | Indirect | |
| Aug 19, 2025 | Common Stock | SSaleDisposed | −590 | $20.00 | −$11,800 | 929,409 | Indirect |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F2
This transaction was executed in multiple trades at prices ranging from $19.75 to $20.715. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The original Form 4, filed August 20, 2025, did not reflect the stock sale on August 20, 2025.
- F2
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
- F3
This transaction was executed in multiple trades at prices ranging from $20.00 to $20.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.